Surgical resection is the standard of care for colorectal metastases isolated to the liver.
However, only 10–25% of the patients are eligible for resection because of extent and …

Colorectal cancer is one of the leading causes of death from malignant diseases in the
Western world. Worldwide,∼ 50% of patients who present with colorectal cancer will …

PURPOSE: To evaluate computed tomography (CT)-guided brachytherapy in patients with
very large liver malignancies or with liver tumors located adjacent to the liver hilum …

Background In a previous phase I–II study we demonstrated that the FOLFOXIRI regimen
[irinotecan 125–175 mg/m 2 day 1, oxaliplatin 100 mg/m 2 day 1, l-leucovorin (l-LV) 200 …

Background: Irinotecan is a topoisomerase I inhibitor that has been approved for use as a
first-and second-line treatment for colorectal cancer. The response to irinotecan is variable …

With more data on the use of oxaliplatin and irinotecan available, and the recent approval of
two signal transduction inhibitors for patients with advanced colorectal cancer, there are now …

Purpose. The clinical trials of vascular endothelial growth factor (VEGF) inhibitors are
discussed. Summary. The recent approval of bevacizumab (a recombinant humanized …

For more than 40 years, 5-fluorouracil (5-FU) has been the mainstay of treatment for patients
with metastatic colorectal cancer. Being the only drug available for such a long time, much …

BACKGROUND: Liver resection remains the best treatment option for patients with
colorectal cancer liver metastases. Major effort on the part of interdisciplinary groups has …

Colorectal cancer (CRC) is the third most common type of cancer and accounts for 11% of
cancers in men and women [1]. This year, approximately 150,000 new cases of colorectal …